On July 30, 2021 Prescient Therapeutics (PTX) reported that it has summarised its operations and cashflow for the June quarter (Press release, Prescient Therapeutics, JUL 30, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-advances-clinical-studies-in-june-quarter [SID1234585506]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.

In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).

This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn’t observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.

Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.

A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.

In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.

Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.

The healthcare stock ended the quarter with $16.09 million in cash.

Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.